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Abstract
Background: Given the considerable toxicity and modest benefit of adjuvant chemotherapy for
non-small cell lung cancer (NSCLC), there is clearly a need for new treatment modalities in the
adjuvant setting. Active specific immunotherapy may represent such an option. However, clinical
responses have been rare so far. Manipulating the host by inducing lymphopenia before vaccination
resulted in a magnification of the immune response in the preclinical setting. To evaluate feasibility
and safety of an irradiated, autologous tumor cell vaccine given following induction of lymphopenia
by chemotherapy and reinfusion of autologous peripheral blood mononuclear cells (PBMC), we are
currently conducting a pilot-phase I clinical trial in patients with NSCLC following surgical
resection. This paper reports on the first clinical experience and evidence of an immune response
in patients suffering from NSCLC.
Methods: NSCLC patients stages I-IIIA are recruited. Vaccines are generated from their resected
lung specimens. Patients undergo leukapheresis to harvest their PBMC prior to or following the
surgical procedure. Furthermore, patients receive preparative chemotherapy (cyclophosphamide
350 mg/m2 and fludarabine 20 mg/m2 on 3 consecutive days) for induction of lymphopenia followed
by reconstitution with their autologous PBMC. Vaccines are administered intradermally on day 1
following reconstitution and every two weeks for a total of up to five vaccinations. Granulocyte-
macrophage-colony-stimulating-factor (GM-CSF) is given continuously (at a rate of 50 µg/24 h) at
the site of vaccination via minipump for six consecutive days after each vaccination.
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Results: To date, vaccines were successfully manufactured for 4 of 4 patients. The most common
toxicities were local injection-site reactions and mild constitutional symptoms. Immune responses
to chemotherapy, reconstitution and vaccination are measured by vaccine site and delayed type
hypersensitivity (DTH) skin reactions. One patient developed positive DTH skin tests so far.
Immunohistochemical assessment of punch biopsies taken at the local vaccine site reaction
revealed a dense lymphocyte infiltrate. Further immunohistochemical differentiation showed that
CD1a+ cells had been attracted to the vaccine site as well as predominantly CD4+ lymphocytes.
The 3-day combination chemotherapy consisting of cyclophosphamide and fludarabine induced a
profound lymphopenia in all patients. Sequential FACS analysis revealed that different T cell subsets
(CD4, CD8, CD4CD25) as well as granulocytes, B cells and NK cells were significantly reduced.
Here, we report on clinical safety and feasibility of this vaccination approach during lymphoid
recovery and demonstrate a patient example.
Conclusion: Thus far, all vaccines were well tolerated. The overall trial design seems safe and
feasible. Vaccine site reactions associated with infusion of GM-CSF via mini-pump are consistent
with the postulated mechanism of action. More detailed immune-monitoring is required to evaluate
a potential systemic immune response. Further studies to exploit homeostasis-driven T cell
proliferation for the induction of a specific anti-tumor immune response in this clinical setting are
warranted.
Background
There are approximately 170,000 new cases of lung cancer
in the United States each year and almost 160,000 annual
deaths, clearly demonstrating that despite progress in the
treatment of this disease over the past two decades, there
are still few long-term survivors: only 12% of all patients
will ever be cured of this devastating disease. Clearly, there
is still an unmet medical need for new adjuvant therapies
that demonstrate efficacy in lung cancer with less associ-
ated toxicity than chemotherapy. The unfortunate reality
is, however, that the field of lung cancer immunotherapy,
which may provide a valid alternative for cytotoxic agents,
lags behind similar efforts with other kinds of tumors, pri-
marily melanoma, prostate and breast carcinoma.
The sources of tumor antigens in cancer vaccine strategies
include isolated peptides, tumor cell lysates, or whole
tumor cells from either autologous tumor or established
allogeneic tumor cell lines. In the case of NSCLC, the
immunodominant antigens are unknown, making devel-
opment of relevant peptide vaccines challenging.
Furthermore, NSCLC is composed of a mixture of histo-
logical subtypes, making selection of one or two relevant
allogeneic cell lines that will encompass the full antigenic
diversity of NSCLC difficult.
The rationale for cancer vaccine therapy is to modify rela-
tively non-immunogenic tumors to induce a tumor-spe-
cific immune response in the host. Cancer cell vaccines,
genetically modified to secrete immunomodulatory
cytokines, have generated potent anti-tumor immunity in
pre-clinical animal models of melanoma, lymphoma,
colon, renal, lung, and prostate cancer. A comparison
involving multiple cytokine genes found that granulocyte-
macrophage colony-stimulating factor (GM-CSF) gene-
transduced vaccines were by far the most potent inducers
of long-lasting specific tumor immunity in one animal
model [1]. Secretion of GM-CSF by genetically-modified
tumor cells stimulates cytokine release at the vaccine site
to activate antigen-presenting cells, which prime CD4+
and CD8+ T cells to recognize circulating tumor-associ-
ated antigens, thereby inducing a tumor-specific cellular
immune response. Induction of a tumor-specific humeral
immune response and activation of a granulocytic (e.g.,
eosinophils and neutrophils) inflammatory reaction may
also contribute to the efficacy of this approach. Early-
phase human clinical trials of GM-CSF-secreting autolo-
gous tumor cells in lung cancer have demonstrated the rel-
ative safety of this treatment approach as well as the
induction of tumor-specific immune responses and evi-
dence of anti-tumor activity [2,3]. However, objective
response rates are still low.
It has previously been reported that immune modulating
doses of cyclophosphamide enhance vaccine-induced
anti-tumor immune responses by inhibiting suppressor T
cell activity [4,5]. Several clinical trials have since com-
bined cyclophosphamide with vaccination. Cyclophos-
phamide and another chemotherapeutic agent,
fludarabine, have been administered together in the treat-
ment of CLL [6] and low-grade non-Hodgkin's Lym-
phoma [7]. The same combination has been administered
in a clinical study of non-myeloablative chemotherapy
and adoptive transfer of highly selected tumor-reactive T
cells to treat patients with metastatic melanoma [8]. These
patients were reinfused with in vitro expanded tumor-
infiltrating T cells followed by IL-2 therapy. This studyJournal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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clearly documented the safety of this conditioning regi-
men in combination with adoptive T cell transfer and
demonstrated an objective response in 6 of 13 patients.
The adoptive transfer of in vitro expanded tumor-infiltrat-
ing lymphocytes exceeds, however, the technical and
financial resources of most laboratories. We hypothe-
sized, therefore, that inhibiting the activity of regulatory T
cells and exploiting the increased sensitivity of lym-
phocytes to respond to antigenic stimuli when placed
under conditions of homeostasis-driven proliferation [9-
12] might be possible when preparative chemotherapy,
reconstitution with autologous PBMC and vaccination
with irradiated, autologous tumor cells are combined. In
preclinical experiments, this was modeled by vaccinating
lymphopenic mice with a GM-CSF gene-modified
melanoma cell line following reconstitution with naïve
spleen cells. Subsequent examination of tumor vaccine-
draining lymph node T cells revealed a substantial
increase in the frequency of activated T cells [13]. Follow-
ing in vitro activation these T cells contained a signifi-
cantly elevated frequency of tumor-specific CD4+ and
CD8+ T cells with augmented function in vitro and thera-
peutic efficacy in vivo. Three possible explanations for the
beneficial effect of combining lymphopenia with recon-
stitution and vaccination are: 1) creation of space (physi-
cal space as well as reduced competition for cytokines), 2)
depletion of regulatory T cells and 3) direct anti-tumor
effect ("softening-up the tumor").
Based upon these observations we initiated a pilot-Phase
I clinical trial for patients with NSCLC made lymphopenic
by preparative chemotherapy and reconstituted with
autologous PBMC prior to vaccination with their autolo-
gous tumor cells. Here, we present our first clinical experi-
ence and evidence of an immune response.
Methods
Patients
This pilot-phase I clinical trial is performed at the Depart-
ment of Surgery – Grosshadern Medical Center of the Lud-
wig-Maximilians-University (LMU) Munich, Germany.
The clinical trial protocol received approval of the ethics
committee of the LMU Munich (registration number 291/
04) and the Bavarian government. All patients enrolled
sign informed consent and all procedures are carried out
in compliance with the Helsinki declaration. Patients are
eligible for enrollment if they have histologically con-
firmed NSCLC stages I-IIIA (surgically resectable), an East-
ern Cooperative Oncology Group performance status of 0
or 1, age ≥ 18 years, an oxygen saturation ≥ 90% on ≤ 2L
supplemental oxygen, a forced expiratory volume in one
second (FEV1) ≥ 40% of predicted, a CD4+ cell count >
200/mm3, and are ≥ 4 weeks from chemotherapy and ≥ 2
weeks from radiotherapy and systemic corticosteroid
treatment. Patients are excluded if they are pregnant, have
any known hypersensitivity to components of the vaccine
or any of the study drugs or have any uncontrolled medi-
cal problems which are considered high risk to take part
in this clinical trial. Patients are further excluded for the
following reasons: previous treatment with cancer vac-
cines or gene therapy, active autoimmune disease, or
infection with human immunodeficiency virus. All
patients undergo staging scans, pulmonary function test-
ing and routine hematology and chemistry analysis as
considered standard prior to open lung surgery. Addi-
tional hematological criteria have to be met prior to col-
lection of the leukaphereses for immune-monitoring and
reconstitution of the patients: Total white blood cell count
(WBC)  ≥ 2500/mm3 and/or absolute neutrophil count
(ANC) > 1000/mm3, hemoglobin > 8.0 g/dL, platelet
count > 100,000/mm3, and Hct > 24%.
Vaccine preparation
Tumor procurement is performed according to accepted
standards of surgical practice. This protocol requires com-
plete tumor resection. A tissue sample is submitted for
definite histopathological assessment and confirmation
of the diagnosis of NSCLC. The remaining tumor is proc-
essed immediately to a single-cell suspension by physical
mincing and enzymatic digestion using a triple enzyme
solution containing 0.02 mg/ml deoxyribonuclease I,
0.25 mg/ml collagenase and 0.1 mg/ml hyaluronidase
(Sigma-Aldrich, Taufkirchen, Germany). Cells are washed
and irradiated at 10,000 rads to prevent cell proliferation.
Cells are then aliquoted into vials in a formulation con-
taining 10% dimethylsulfoxide (DMSO) (Sigma-Aldrich,
Taufkirchen, Germany), 45% RPMI-1640 medium (Cam-
brex Bio Science, Verviers, Belgium) and 45% autologous
serum of the corresponding patient, and are then cryopre-
served. Vaccine cells are tested for tumor cell dose, viabil-
ity, endotoxin, and sterility. Individual patient vaccines
that do not meet release criteria are not be used and the
corresponding patients are not enrolled for vaccine treat-
ment. Before clinical administration, cryopreserved cells
are thawed, washed extensively, and resuspended in 1 mL
of sterile saline for the vaccines and 0.5 mL for cells used
in delayed-type hypersensitivity testing. Additional tumor
cells (depending on the total number of tumor cells avail-
able) are stored frozen or placed into culture for immune-
monitoring purposes. The vaccine dose is individualized
for each patient based upon tumor cell yield but is
required to be at least 5 × 106 tumor cells/dose. The dose
for each vaccination is equivalent. The minimum total
vaccine dose required for treatment is 25 × 106 tumor cells
(5 × 106 cells × 5 vaccinations). Aliquots of 1 × 106 tumor
cells are set aside for use in DTH testing.Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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Treatment and evaluation
The treatment schedule is illustrated in Figure 1. Based on
the available preclinical and clinical data, we have initi-
ated this pilot study assessing the safety and efficacy of an
autologous NSCLC tumor cell vaccine administered with
immunomodulatory doses of cyclophosphamide and
fludarabine. In this protocol the vaccine is administered
intradermally (Figure 2). The intradermal route of admin-
istration was selected in order to ensure close approxima-
tion of the antigen and GM-CSF to the intradermal
dendritic cells which are involved in tumor-associated
antigen presentation to host T cells.
Following the enrollment screening, all patients signed
informed consent and underwent the standard surgical
procedure which consisted of (bi-) lobectomy and medi-
astinal/hilar lymphadenectomy. Following sufficient
recovery from the surgical procedure two leukaphereses
were harvested, one for later reconstitution and one for
immune monitoring purposes. Leukaphereses were per-
formed using a continuous flow cell separator (Cobe
Spectra, Gambro GmbH, Planegg, Germany). Aphareses
products were analyzed by flow cytometry (see methods
below), frozen in DMSO and stored above liquid nitrogen
according good manufacturing practice (GMP) until rein-
fusion. All patients then received preparative chemother-
apy consisting of cyclophosphamide (350 mg/m2 IV) and
fludarabine (20 mg/m2 IV) at days 1–3 prior to the first
vaccination. The induction of lymphopenia was followed
by reinfusion of PBMC (leukapheresis product) and the
intradermal administration of the first vaccine. Immedi-
ately following the vaccine application, the subcutaneous
catheter for instillation of GM-CSF (Leukine®, Berlex Lab-
oratories Inc., Richmond, CA, USA) via the infusion min-
ipump is placed locally in the center area of the vaccine
site (Fig. 2). GM-CSF is infused over six full days at a rate
of 50 µg/24 h.
Patients receive intradermal vaccine injections every two
weeks for a total of up to five vaccine cycles. The dose is
individualized for each patient based on vaccine yield and
ranges from 14 × 106 – 100 × 106 tumor cells/vaccination.
Immunologic response to vaccination is monitored by
delayed-type hypersensitivity (DTH) skin testing to injec-
tions of autologous tumor cells at base line and 48 h fol-
lowing the fourth vaccine. After completion of the trial
protocol a third leukapheresis is harvested for immune-
monitoring purposes. Patients then continue to have
Outline of the clinical trial protocol Figure 1
Outline of the clinical trial protocol. Non-small cell lung cancer patients stages I-IIIa undergo curative surgery to prepare 
an autologous vaccine. The autologous tumor cells are physically minced and digested by a triple enzyme solution. The vaccine 
is then irradiated at 10,000 rads, tested for sterility and cryopreserved. Immediately following the intradermal vaccination 
(biweekly, total of up to five vaccinations) GM-CSF is infused subcutaneously for 6 days at a rate of 50 µg/24 h. Prior to vacci-
nation plus GM-CSF administration, lymphopenia is induced by a 3-day combination chemotherapy (cyclophosphamide 350 mg/
m2 and fludarabine 20 mg/m2) followed by reconstitution with autologous peripheral blood mononuclear cells. Two additional 
leukaphereses are harvested pre- and post-vaccination for immunemonitoring purposes. (CTX: chemotherapy)Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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monthly immune surveillance in addition to their stand-
ard clinical observation every 3 months.
Delayed type hypersensitivity (DTH) tests
To evaluate cell-mediated reactivity induced by applica-
tion of autologous tumor cells DTH tests were perfomed
at baseline (before induction of lymphopenia) and 48 h
following the fourth vaccine. DTH skin tests consisted of
0.5 mL containing an estimate of 106 cells. The cells were
injected intradermally into the upper arm and read 48 h
later. DTH skin tests were considered positive if an ery-
thematous and indurated area measuring at least 5 mm
appeared.
Immunohistochemistry and flow cytometry
Punch biopsies were taken at the vaccine site and an unaf-
fected skin site as a control. In brief, tissues were fixed in
10% neutral buffered formalin, processed routinely and
embedded in paraffin. Specimens were stained with
hematoxylin/eosin and assessed immunohistochemically
for CD3, CD4, CD8 and CD1a (as a marker for dendritic
cells) using the corresponding monoclonal antibodies
(Biozol GmbH, Eching, Germany).
Based on the available preclinical and early clinical data,
we hypothesized that vaccination during a phase of lym-
phoid recovery may result in a greater tumor-specific
immune response. To investigate whether our condition-
ing regimen with preparative chemotherapy and reinfu-
sion of autologous PBMC actually induced a homeostatic-
driven lymphocyte proliferation phase, we assessed differ-
ent lymphocyte subsets over the time course of the clinical
trial protocol using fluorescence activated cell sorting
(FACS). PBMC were stained for 30 min, washed in FACS
buffer, and fixed in 1% paraformaldehyde in PBS. Mono-
clonal antibodies and isotype controls were used for CD3,
CD4, CD8, CD16, CD19, CD25, CD56 (BD Biosciences,
Heidelberg, Germany) Acquisition of data was performed
on FACS-Calibur flow cytometer (BD Biosciences, Heidel-
berg, Germany), and data was analyzed using WINMDI28
software [14].
Results
Patient characteristics
To date, 4 patients were enrolled in the trial, 2 males and
2 females. The age range at diagnosis was 49 – 78. All
patients had a performance status of 0 according to the
Eastern Cooperative Oncology Group (ECOG) scale.
None of the patients showed evidence of metastatic dis-
ease as evaluated by CTscan, PETscan and/or skeletal szin-
tigraphy. Three patients underwent lobectomy and 1
patient a bilobectomy with all patients getting a standard
systematic hilar/mediastinal lymphadenectomy. Different
histopathologic subgroups of NSCLC were represented
with adenocarcinoma, squamous cell carcinoma and
large-cell carcinoma. There were no serious adverse events
associated with the surgical procedures. None of the
patients had prior systemic therapy including chemother-
apy and immunotherapy. One patient withdrew by choice
before initiation of the treatment phase. Thus far, 3
patients completed the study protocol including prepara-
tive chemotherapy, reconstitution of autologous PBMC,
vaccination and post-vaccination leukapheresis for
immunemonitoring purposes. All patients on the trial
refused standard adjuvant chemotherapy as recom-
mended by the medical oncologist. The longest follow up
A. Intradermal application on the abdominal wall; B. Continuous infusion of GM-CSF at the vaccine site using a minipump Figure 2
A. Intradermal application on the abdominal wall; B. Continuous infusion of GM-CSF at the vaccine site using 
a minipump. Vaccines are administered intradermally on alternating sides of the abdominal wall (A). Before clinical adminis-
tration, the irradiated autologous tumor cells are thawed, washed extensively, and resuspended in 1 mL of sterile saline. Imme-
diately following the vaccine application a catheter is placed at the vaccine site and GM-CSF is infused continuously at a rate of 
50 µg/24 h for a total of 6 days using an osmotic minipump (Smiths Medical, Kirchseeon, Germany) (B).Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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period with 17 months was that of the first patient
enrolled. Table 1 summarizes the baseline patient charac-
teristics.
Vaccine production, administration and delivery of GM-
CSF
Solid tumors were processed to a single cell suspension by
mechanical mincing and enzymatic digestion. Vaccine
production was successful in 4 of 4 patients. All tumor
specimens were processed fresh. Wet tumor weight ranged
from 11 – 31 grams (mean: 20 grams). The average tumor
cell number obtained was 27.9 × 108 cells per gram wet
tumor (range 1.8 – 105 × 108). The viability of cells as
assessed by trypan blue staining ranged from 1% to 55%.
Sterility of the vaccine following irradiation at 10,000 rads
was confirmed in all cases. The average number of days
from tumor harvest to the first vaccination was 52.3
(range 48 – 57). All tumor harvests met the minimum
requirement for tumor cell number of 5 × 106 per vaccine
(total of 25 × 106 for all 5 vaccinations). Table 2 summa-
rizes the vaccination details. Following each vaccination
GM-CSF (Leukine®, Berlex Laboratories Inc., Richmond,
CA, USA) was infused subcutaneously at the vaccination
site for 6 full days at a rate 50 µg/24 h using an osmotic
minipump (Smiths Medical, Kirchseeon, Germany) (Fig-
ure 2). This technique turned out to be technically feasible
and easily tolerable for the patients.
Reconstitution of lymphopenic patients and lymphoid 
recovery
Following 3 days of conditioning chemotherapy with
cyclophosphamide (350 mg/m2) and fludarabine (20
mg/m2) all patients received the leukapheresis product
harvested earlier. The first vaccine was administered 24 h
following the reconstitution with the reinfusion of PBMC
being administered 48 h following the last dose of chem-
otherapy. A mean of 1.3 × 1010 nuclear cells (range 0.9 –
2.1 × 1010 cells) was reinfused. An average of 54% of the
cells (range 39 – 71%) were recognized as lymphocytes
using FACS analysis. 75% of the lymphocytes were CD3
positive (range 65 – 81%) with 58% (range 52 – 65%)
and 18% (range 12 – 22%) being CD4 and CD8 positive,
respectively. Table 2 summarizes the characteristics of the
reinfused mononuclear cells.
FACS analysis of PBMC was performed at different time
points throughout the course of the treatment phase to
investigate whether the chosen protocol actually induces
a homeostatic-driven lymphocyte proliferation/recovery
phase that may be taken advantage of by applicating
repeated tumor cell vaccinations. The combination chem-
otherapy induced a profound lymphopenia in all patients
with low total white blood cell counts and absolute lym-
phocyte counts. All of the determined CD3 positive cell
subsets (CD4, CD8, CD4CD25) were affected. Neutrophil
counts recovered to pre-chemotherapy levels within 30
days. Recovery of different T cell subsets (CD4, CD8,
CD4CD25) was slower in all patients but varied inter-
individually. The post-chemotherapy increase in CD4
numbers followed the same kinetics as the other subsets.
One patient experience an extended depression of CD19-
positive B lymphocytes, whereas NK cells (CD3-
CD16+CD56+) came back within 30 days in all patients.
Red blood cell and platelet counts were not affected signif-
icantly. A patient example is given below.
Tumor-related immunity
Injections of irradiated, autologous NSCLC cells com-
bined with local infusion of GM-CSF following prepara-
tive chemotherapy and reconstitution with autologous
PBMC elicited local vaccine site reactions in all patients.
Intensity and frequency of the responses varied but gener-
ally increased with the number of vaccines administered.
Clinically, the reactions were characterized by local ery-
thema and induration (Figure 3). One patient with a
strong local vaccine site reaction also reported recall
responses at the site of a previous injection and the base-
line DTH injection site.
Irradiated, dissociated, autologous NSCLC cells were
available for DTH testing in all patients. Although 3/3
patients developed local vaccine site reactions, a positive
DTH skin test was observed in only one patient 48 h fol-
Table 1: Patient characteristics
Patient Gender/Age Prior Therapies Surgerya Histology Tumor stage Performance 
statusc
1 F/78 none upper bilobectomy adenocarcinoma IIIA 0
2 F/47 none lobectomy squamous-cell 
carcinoma
IB 0
3 M/65 none lobectomy large-cell 
carcinoma
IIA 0
4 b M/77 none lobectomy adenocarcinoma IB 0
a all patients received standard systematic hilar/mediastinal lymphadenectomy
b patient withdrew by choice before the treatment phase
c Eastern Cooperative Oncology Group (ECOG) scaleJournal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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lowing the fourth vaccine. None of the DTH tests were
positive before the vaccination phase.
Histopathological assessment of punch biopsy specimens
taken at the local vaccine site reaction 48 h following the
third vaccine revealed a dense infiltrate consisting pre-
dominantly of macrophages, eosinophils, neutrophils
and lymphocytes (Figure 3). In contrast to unrelated skin
sites, CD1a-positive dendritic cells were present at the vac-
cine site. Further immunohistochemical staining showed
that most of the infiltrating lymphocytes in the patient
with the strongest vaccine site reaction were CD4-positive
cells.
Toxicity
Vaccination consistently induced grade 1 to 2 erythema
and induration at the injection sites on the abdominal
wall. Local pruritus was also reported. Occasional grade 1
to 2 fatigue and flu-like symptoms were observed. There
were no significant hepatic, renal, pulmonary, cardiac,
hematologic, gastrointestinal or neurologic toxicities
attributable either to preparative chemotherapy, reinfu-
sion of autologous PBMC or the vaccine. No severe
autoimmune phenomena such as pericarditis, hypophysi-
tis or vasculitis were noted. However, one patient reported
persistent myalgias and joint pain. In this patient, a tran-
sient elevation of markers such as rheumatoid factor and
antinuclear antibodies was detectable, potentially indicat-
ing a temporary autoimmune activation.
Hematologic toxicities due to the conditioning chemo-
therapy were transient and did not require transfusion
therapy. Low absolute neutrophil counts, low absolute
lymphocyte counts, and the transient depression of
CD19-positive B cells were observed in all patients. No
typical opportunistic infections such as Herpes zoster or
Pneumocystis carinii were detected.
No serious adverse events attributable to the local infu-
sion of GM-CSF were detected.
Clinical course and patient example
In the present study, NSCLC patients were vaccinated as
an adjuvant therapy without detectable tumor manifesta-
tion following surgery. Therefore, no target lesions were
available for monitoring of a potential clinical response to
treatment. Nevertheless, all patients on this trial were
assessed at 3-months intervals by means of clinical exam-
ination, determination of specific tumor markers and
radiographs (CTscan). To date, all patients on the trial
remain without relapse with the longest follow-up period
being 17 months for the first enrolled patient (patient 1,
Table 1).
Figure 4 shows the chest X-ray and thoracic MRI of patient
1 with an obvious tumor mass originating from the upper
lobe of the right lung. The patient was resected with an
upper bilobectomy (pT2 pN2, IIIA) and refused the stand-
ard adjuvant treatment for resected stage IIIA NSCLC con-
sisting of chemotherapy. Following successful vaccine
production and recovery from the surgical procedure the
patient underwent preparative chemotherapy, reconstitu-
tion with autologous PBMC and repeated vaccinations as
described above.
Figure 5 illustrates the time course of lymphoid recovery
following induction of lymphopenia by preparative
chemotherapy as seen in patient 1. The patient was recon-
stituted with 0.9 × 1010 autologous PBMC (5.05 × 107
CD3-positive cells/kg) followed by 5 cycles of autologous
tumor cell vaccine. All of the determined CD3-positive
cell subsets (CD4, CD8, CD4CD25) were affected by
cyclophosphamide and fludarabine. As seen in all
patients, neutrophil counts recovered to pre-chemother-
apy levels within 30 days. Recovery of different T cell sub-
sets (CD4, CD8, CD4CD25) was slower than
normalization of neutrophil counts in all patients but var-
Table 2: Vaccination details and characteristics of reinfused mononuclear cells
Reinfused leukapheresis producta
Patient Tumor 
weight 
[gram]
Tumor cell 
yield
No. of tumor 
cells/vaccine
No. of nuclear 
cells
% lympocytes % CD3+c %CD4+/
%CD8+c
11 1 1 . 8  ×  1 0 8 2 × 107 0.9 × 1010 39 81 65/19
23 1 1 0 5  ×  1 0 8 10 × 107 2.1 × 1010 53 79 57/22
32 4 1 . 9  ×  1 0 8 1.4 × 107 0.9 × 1010 71 65 52/12
4 b 14 2.8 × 108 n.a. n.a. n.a. n.a. n.a.
a PBMC were reinfused following 3 days of preparative chemotherapy (cyclophosphamide 350 mg/m2 and fludarabine 20 mg/m2)
b patient withdrew by choice before the treatment phase
c shown as percentage of lymphocytes
n.a. not applicableJournal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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Local vaccine site reaction and immunohistochemistry of punch biopsies Figure 3
Local vaccine site reaction and immunohistochemistry of punch biopsies. (A) Typical vaccine site reaction 48 h fol-
lowing the third vaccination. Clinically, the reaction was characterized by erythema, induration and pruritus. Note the catheter 
for local infusion of GM-CSF placed in the center of the vaccine application site. Punch biopsies were taken at the reaction site 
and assessed immunohistochemically. Histopathological assessment of punch biopsy specimens taken at the local vaccine site 
reaction 48 h following the third vaccine revealed a dense infiltrate consisting predominantly of macrophages, eosinophils, neu-
trophils and lymphocytes (B, ×100). In contrast to unrelated skin sites, CD1a-positive dendritic cells were present at the vac-
cine site (C, ×400). Further immunohistochemical staining showed that most of the CD3-positive lymphocytes (D, ×400) in the 
patient with the strongest vaccine site reaction were CD4-positive cells (E, ×100).Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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ied inter-individually. The post-chemotherapy increase in
CD4 numbers followed the same kinetics as the other sub-
sets with no extended depression as one might expect fol-
lowing fludarabine treatment. Patient 1 experienced an
extended depression of CD19-positive B lymphocytes,
whereas NK cells (CD3-CD16+CD56+) returned within
30 days (as observed in all patients).
Discussion
Lung cancer vaccines have progressed from pre-clinical to
clinical studies [3,15,16] and potentially represent a novel
and safe form of treatment that is urgently needed consid-
ering the toxicity and modest benefit of existing adjuvant
therapies for NSCLC. However, effectiveness of lung can-
cer vaccines has yet to be established. We hypothesized
that vaccines for lung cancer (and other cancers) fail
because the magnitude of the anti-tumor response is
insufficient to mediate tumor regression. Elimination of
regulatory T cells (Tregs) and "creation of space" prior to
vaccination may augment the immune response and vac-
cine efficacy. Here, we report for the first time on early
clinical results of an autologous lung cancer vaccine
administered to patients who have been made lympho-
penic by preparative chemotherapy and reconstituted
with autologous PBMC. To our knowledge, this is also the
first attempt to use an osmotic minipump for the contin-
uous delivery of GM-CSF as an adjuvant to the vaccine
site.
Adjuvant vaccination
With few exceptions, most early phase clinical trials eval-
uating lung cancer vaccines enroll patients with late-stage
disease (stages IIIA-IV). In these patients, a median sur-
vival of 11 months may be achieved using established
treatment modalities such as chemotherapy and radio-
therapy. Tumor-induced immune suppression and com-
promised performance status may contribute to the
limited efficacy of active-specific immunotherapy for this
group of patients. It seems obvious to move to the adju-
vant setting where immunosuppressive influences may
have been removed through tumor resection and poten-
tially remaining tumor cells are referred to as minimal
residual disease. In accordance with this hypothesis,
patient 1 on our trial failed the first enrollment screening
with less than 200 CD4+ cells/mm3, but was eligible fol-
lowing surgery when her CD4 cell count had recovered,
indicating a possible immunosuppressive effect of the
tumor (Figure 5). Other groups also investigated adjuvant
vaccination for lung cancer such as recombinant MAGE-
A3 fusion protein vaccination where a large Phase III clin-
ical trial is currently being initiated [17].
Baseline chest x-ray (left) and MRI scan (right) of patient 1 Figure 4
Baseline chest x-ray (left) and MRI scan (right) of patient 1. Note the large tumor originating from the upper right lobe 
of the lung (arrows). The patient was resected with an upper bilobectomy (pT2 pN2, IIIA) and systematic lymphadenectomy 
and the diagnosis of NSCLC (adenocarcinoma) was confirmed.Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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Analysis of absolute white blood cell count (WBC), neutrophil count and flow-cytometric assessment of lymphocytes, T cell  subsets and natural killer cells in patient 1 during the treatment phase Figure 5
Analysis of absolute white blood cell count (WBC), neutrophil count and flow-cytometric assessment of lym-
phocytes, T cell subsets and natural killer cells in patient 1 during the treatment phase. After preparative chemo-
therapy (CTX) (cyclophosphamide 350 mg/m2 and fludarabine 20 mg/m2) the patient was reconstituted with 0.9 × 1010 
autologous PBMC (5.05 × 107 CD3-positive cells/kg) followed by 5 cycles of the autologous tumor cell vaccine. All of the 
determined CD3-positive cell subsets (CD4, CD8, CD4CD25) were affected by cyclophosphomide and fludarabine. As seen in 
all patients, neutrophil counts recovered to pre-chemotherapy levels within 30 days. Recovery of different T cell subsets (CD4, 
CD8, CD4CD25) was slower than normalization of neutrophil counts in all patients but varied inter-individually. The post-
chemotherapy increase in CD4 numbers followed the same kinetics as the other subsets with no extended depression as one 
might expect following fludarabine treatment. Patient 1 experienced an extended depression of CD19-positive B lymphocytes, 
whereas NK cells (CD3-CD16+CD56+) recovered within 30 days (as observed in all patients). Additional leukaphereses were 
harvested prior to preparative chemotherapy and after the vaccination phase.Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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Vaccinating during lymphoid recovery
Recently, different groups have identified an approach
that exploits the increased sensitivity of lymphocytes to
respond to antigenic stimuli when they are placed under
conditions of homeostasis-driven proliferation [9-13,18]
(reviewed in [19,20]). In the preclinical setting, this was
modeled by vaccinating lymphopenic mice with a GM-
CSF gene-modified melanoma cell line following recon-
stitution with naïve spleen cells. The reconstitution step
provided a broad repertoire of non-damaged T cells to the
vaccinated host. Subsequent examination of tumor vac-
cine-draining lymph node T cells from reconstituted-lym-
phopenic mice revealed a substantial increase in the
frequency of activated T cells when compared to lymph
node T cells from normal mice [13]. Following in vitro
activation these T cells contained a significantly elevated
frequency of tumor-specific CD4 and CD8 T cells with
augmented function in vitro and therapeutic efficacy in
vivo. Three explanations for the beneficial effect of com-
bining lymphopenia with reconstitution and vaccination
may be: 1) creation of space (physical space as well as
reduced competition for cytokines such as IL-7 or IL-15
[12,21]), 2) depletion of regulatory T cells [22] and 3)
direct anti-tumor effect (softening-up the tumor). The
combination chemotherapy used in our trial (cyclophos-
phamide/fludarabine) has little anti-NSCLC activity and a
direct anti-tumor effect is unlikely in this adjuvant setting.
Nonetheless we employed this strategy because of its
immune amplifying potential. Dudley and coworkers [8]
pretreated melanoma patients with a "non-myeloabla-
tive" chemotherapy regimen consisting of 2 days of cyclo-
phosphamide at 60 mg per kg of body weight, followed by
5 days of fludarabine at 25 mg/m2. On the day after the
final dose of fludarabine, when circulating lymphocyte
and neutrophil counts had dropped to less than 20/mm3,
each patient received an intravenous infusion of autolo-
gous tumor-infiltrating lymphocytes (TIL) that had been
expanded in vitro. Infused cells expanded and persisted in
a majority of patients and were associated with a higher
objective response rate than adoptive immunotherapy
with TIL alone. A single, low, intravenous dose (usually
300 mg/m2 to a maximum of 600 mg) of cyclophospha-
mide was administered before immunotherapy in other
studies [11,15,23]. This enhanced the effect of immuno-
therapy. In various animal models, cyclophosphamide
has demonstrated its ability to augment DTH responses,
increase antibody production, abrogate tolerance, and
potentiate antitumor immunity [11,23]. With 3 consecu-
tive days of 350 mg/m2cyclophosphamide and 20 mg/m2
fludarabine, we chose a dose lower than that of Dudley et
al. but more potent to induce lymphopenia than single
doses of a maximum of 600 mg cyclophosphamide. In
our trial we observed lymphocyte but not neutrophil
counts below 200/mm3 in all patients. The question, how-
ever, on how lymphopenic patients need to be in order to
augment the immune response to an autologous vaccine
remains to be answered.
To our knowledge this is the first report to combine lym-
phopenia, reconstitution and vaccination in the adjuvant
clinical setting in lung cancer patients. Powell and cow-
orkers [24] have performed a highly sophisticated trial in
melanoma patients where non-myeloablative chemother-
apy was combined with an infusion of in vitro-stimulated,
gp100 peptide-reactive, autologous PBMC, high-dose IL-2
therapy and vaccination with gp100:209–217(210 M)
peptide. No objective clinical responses where observed
despite persistence of tumor-specific CD8+ T cells. The
authors hypothesize that ineffective cells had been gener-
ated by their approach. Jaffee and coworkers [25] com-
bined an allogeneic GM-CSF-secreting vaccine with
adjuvant chemoradiation in their phase I trial for patients
with surgically resected adenocarcinoma of the pancreas.
In this work, no detailed data is presented if these patients
were made lympopenic through adjuvant chemoradia-
tion. Nonetheless, this trial may represent an example of
vaccination of cancer patients during a phase of lymphoid
recovery. Three patients treated at the highest vaccine dose
level (≥ 10 × 107  vaccine cells) seemed to have an
increased disease-free survival time, remaining disease-
free at least 25 months after diagnosis. Recently, Appay
and coworkers published their results on six patients with
advanced melanoma treated with lymphodepleting
chemotherapy with busulfan and fludarabine, followed
by reinfusion of Melan-A specific CD8+ T cell containing
peripheral blood mononuclear cells and Melan-A peptide
vaccination [26]. One patient presented a partial response
on the clinical level. The approach demonstrated good
feasibility and low toxicity. However, expansion of Melan-
A specific CD8+ T cells in the peripheral blood was mostly
inconsistent and the proportion of circulating CD4+ regu-
latory T cells remained mostly unchanged. Although sim-
ilar in the underlying approach, several differences such as
the treatment of advanced cancer patients, the use of a dif-
ferent lymphodepleting chemotherapy regimen and the
application of a peptide vaccine in combination with
incomplete Freund's adjuvant instead of GM-CSF will
make a direct comparison to our study difficult.
It remains to be seen if our approach using an autologous
vaccine in lymphopenic lung cancer patients is able to
induce tumor-specific T cells that, in turn, have the capa-
bility to find and eliminate potentially remaining tumor
cells following surgical resection of the primary tumor. In
any case, as illustrated in Figure 5, it is feasible to mimic
the preclinical setting described above, in lung cancer
patients receiving preparative chemotherapy to induce
lymphopenia.Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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GM-CSF as vaccine adjuvant
Our data clearly demonstrate that GM-CSF administered
as a continuous infusion at the vaccine site via minipump
is safe as an adjuvant in this setting. Other groups have
used autologous tumor cells (malignant mesothelioma)
in combination with repeated subcutaneous injections of
recombinant GM-CSF (80 µg) failing to induce major
tumor regression despite inducing tumor-specific immu-
nity in 32% of patients [27]. Vaccination with irradiated
NSCLC cells genetically modified to secrete GM-CSF has
demonstrated safety and significant clinical efficacy [2,3].
However, limitations to this approach might be regulatory
hurdles and immune responses directed against the vec-
tors used for transduction of the tumor cells. Furthermore,
a threshold effect for vaccine GM-CSF production on sur-
vival was noted in these trials, with longer survival seen in
patients receiving vaccines secreting >40 ng GM-CSF/106
cells/24 h [3]. However, attempts to have consistently
high GM-CSF secretion at the vaccine site (>2000 ng/106
cells/24 h) induced by a GM-CSF-producing bystander
cell line mixed to the autologous NSCLC cells failed to
show association between either tumor cell dose or GM-
CSF dose and survival [28]. The authors concluded that
adenoviral GM-CSF vectors may provide an adjuvant
effect owing to the presence of residual adenoviral pro-
teins in the vaccine that are not present with the bystander
approach. While the reason for the failure remains
unknown, the significant increase in GM-CSF secretion by
the "bystander" GVAX (25 fold higher than the autolo-
gous vaccine) may have also had a negative effect. In this
context, Serafini and coworkers have reported, that tumor
vaccines that secrete high levels of GM-CSF induce mye-
loid suppressor cells that, in turn, inhibit anti-tumor
immunity [29].
With 50 µg/24 h GM-CSF infused at the vaccine site for 6
full days following each of the 5 vaccinations in our trial,
we chose a moderate dose of GM-CSF. This was sufficient
to induce vaccine site reactions in all patients with the
continuous infusion via the osmotic minipump being a
safe and feasible means for GM-CSF delivery at a constant
dose level. Currently, systemic GM-CSF concentrations
over time are being determined in our trial with results
pending.
Clinical course, tumor-related immunity and toxicities
In this paper we establish that induction of lymphopenia
followed by reconstitution with autologous PBMC and
vaccination with autologous NSCLC cells is both safe and
feasible in the adjuvant setting. Immune responses to vac-
cination were measured by vaccine and DTH skin reac-
tions. Positive vaccine site reactions were observed in 3/3
patients. This is in good accordance with other trials using
autologous NSCLC cells as a vaccine, reporting 81% of
patients developing vaccine site induration, increasing to
90% after repeated vaccinations [2,3]. As observed in
these trials, we saw the most intense vaccine site reaction
in patient 2 receiving the highest tumor cell dose. His-
topathological assessment of punch biopsy specimens
taken at the local vaccine site reaction 48 h following the
third vaccine revealed a dense infiltrate consisting pre-
dominantly of macrophages, eosinophils, neutrophils
and lymphocytes. In contrast to unrelated skin sites,
CD1a-positive dendritic cells were present at the vaccine
site, most of the infiltrating lymphocytes in the patient
with the strongest vaccine site reaction were CD4-positive
cells. Further investigation using anti-CD25 and anti-
FoxP3 (a marker for regulatory T cells) staining is cur-
rently underway to characterize these infiltrating cells.
Positive DTH skin testing was observed in 1/3 patients
(again patient 2 with the highest dose of tumor cells) in
our trial. This mirrors results from other studies using
autologous NSCLC cells as a vaccine approach where the
frequencies of positive DTH skin tests clearly correlated
with the administered vaccine dose [2,3]. In the study
published by Nemunaitis and coworkers [3], DTH testing
was positive in 9% of patients at baseline, after 4 vaccina-
tions 34% of patients tested positive. However, no posi-
tive DTH reactions were detected at vaccine doses with
fewer than 10 × 106 cells.
The most common vaccine-related adverse events in our
study were local vaccine site reactions, followed by consti-
tutional symptoms such as fatigue and mild fever. All
injection site reactions consisted of local, self-limiting ery-
thema, induration and pruritus. Overall no grade 3 or 4
adverse events were observed. Patient 2 reported persist-
ent myalgia and arthralgia which was associated with a
transient elevation of rheumatoid factor and anti-nuclear
antibodies, potentially indicating an autoimmune phe-
nomenon. The same patient also experienced recall
responses at the site of previous injections and the base-
line DTH injection site following the third vaccination.
Most likely, the autologous vaccines manufactured for
this trial also contained cells, such as fibroblasts and
pneumocytes, and may therefore be able to induce clini-
cally detectable autoimmune symptoms. However, no
severe autoimmune disease as observed in other vaccine
trials with melanoma patients [8], was observed here. To
date, all patients on the trial remain without relapse with
the longest follow-up period being 17 months for the first
enrolled patient.
Conclusion
Non-small cell lung cancer is not considered an immune-
sensitive malignancy. However, there is increasing evi-
dence that NSCLC can evoke specific humoral and cellular
antitumor immune responses. Manipulating the host by
preparative chemotherapy and reconstitution with autol-Journal of Translational Medicine 2007, 5:43 http://www.translational-medicine.com/content/5/1/43
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ogous PBMC may augment the vaccine-induced tumor-
specific immune response seen in some patients. Here, we
report that induction of lymphopenia followed by PBMC
reinfusion, combined with an autologous whole tumor
cell vaccine and the continuous infusion of GM-CSF at the
vaccine site, is a safe and feasible approach in resectable
lung cancer patients. Evidence of anti-tumor immunity
induced by this approach is present with positive vaccine-
site reactions in all patients. However, more patients need
to be treated within this protocol in order to be able to
assess and compare clinical outcome.
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